ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BKD / insiders
MD (77) SGRY (66) NHC (72) ARDT (69) ⌘ Pro Terminal β†’

Brookdale Senior Living Inc. (BKD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$10.44 +0.48% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.43

Brookdale Senior Living Inc. (BKD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $2.48B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BKD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Brookdale Senior Living Inc. (NYSE: BKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.44 (+0.48% 1D, market cap $2.48B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BKD ranks #710 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BKD compare to MD and SGRY in the Health Care sector?
β–Ό

Within the Health Care sector (Hospital/Nursing Management), BKD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 26.2%, and ROIC of 0.3%. By comparison, MD (Pediatrix Medical Group Inc.) holds a B+ grade (77/100 RQD, P/E 14.3x, ROIC 33.6%, cap $2.33B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BKD?
β–Ό

Per BKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001332349), Brookdale Senior Living Inc. generated $3.19B in revenue (+2.2% YoY), -$262.7M in net income, and $16.5M in free cash flow against $5.95B in total assets and $4.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.43 (-0.10%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0.5% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk E
Cash (9)Whales (7)SEC (5)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$18 Bull$9 Base$7 Bear
πŸ“¬ FREE BKD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BKD)Realized 20D OHLCV Swing Band: Β±6.7%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY BKD SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($16.5M FCF) & 26.2% Gross Margin

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (22% of score)

20D Institutional Volume Accumulation (Β±6.7% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
24
Grade E$10.12-0.5% Next Q
Q2 (-2Q)
27
Grade E$10.07-5.4% Next Q
Q3 (-1Q)
29
Grade E$9.53+9.5% Next Q
Current
32
Grade E$10.44-9.2% Hist 90D Ξ±
Trajectory: E (24) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BKD Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BKD currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.00) and Max Pain ($10.96) forces dealer call-delta covering toward $17.94.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BKDβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BKD Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BKD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BKD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BKD)

  • βœ“Walkthrough of BKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.53%β–² RESISTANCE BREAKOUT
2026-11-03O $10.27H $10.44L $10.27C $10.44VOL 5.49M
RES: $10.30SUP: $8.62SMA50: $11.00SMA200: $13.31
$16.79$14.80$12.82$10.83$8.84RES $10.30SUP $8.62$10.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BKD Butterfly Map β†’ + Track BKD β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
32.5%/yr Implied 5Y Growth

vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BKD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BKD)

Health Care Rank #710 of 1015 βš”οΈ MD vs BKD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BKD vs. MD, SGRY, NHC, ARDT)

Industry: Hospital/Nursing Management (14 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Brookdale Senior Living Inc. (BKD) ranks #710 by composite RQD confidence (32/100, grade E) and #219 by equity capitalization ($2.48B). Within this direct 5-issuer industry benchmark cohort, ARDT leads on earnings valuation at 12.8x trailing P/E, while MD leads on capital efficiency and profitability with 33.6% ROIC and β€” gross margin. MD currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with BKD at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BKD ACTIVE
Brookdale Senior Living Inc.
E 32/100 β€” 26.2% 0.3% +0.48% $2.48B Benchmark Subject
MD
Pediatrix Medical Group Inc.
B+ 77/100 14.3x β€” 33.6% +2.99% $2.33B /md-vs-bkd β†’
SGRY
Surgery Partners Inc.
C+ 66/100 β€” β€” 9.9% -0.39% $3.04B /sgry-vs-bkd β†’
NHC
National HealthCare Corporation
B 72/100 27.7x β€” 10.1% -1.96% $3.23B /nhc-vs-bkd β†’
ARDT
Ardent Health Inc.
C+ 69/100 12.8x β€” 10.5% -2.49% $1.70B /ardt-vs-bkd β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001332349 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Brookdale Senior Living Inc. (BKD) reported GAAP revenue of $3.19B (+2.2% vs. FY2024 revenue of $3.13B , and +5.9% cumulative change since FY2023) , GAAP net income of -$262.7M, operating cash flow of $218.0M, and free cash flow of $16.5M (+147.1% YoY). On the balance sheet, BKD closed FY2025 with $5.95B in total assets against $4.22B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.19B -$262.7M $218.0M $16.5M $5.95B $4.22B
FY2024 (FY) 2024-12-31 $3.13B -$201.9M $166.2M -$35.1M $6.34B $4.02B
FY2023 (FY) 2023-12-31 $3.02B -$189.0M $162.9M $162.9M β€” β€”

3. BKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Brookdale Senior Living Inc. (NYSE: BKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.44 (+0.48% 1D, market cap $2.48B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BKD ranks #710 in composite RQD confidence.

How does BKD compare to MD and SGRY in the Health Care sector?

Within the Health Care sector (Hospital/Nursing Management), BKD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 26.2%, and ROIC of 0.3%. By comparison, MD (Pediatrix Medical Group Inc.) holds a B+ grade (77/100 RQD, P/E 14.3x, ROIC 33.6%, cap $2.33B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BKD?

Per BKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001332349), Brookdale Senior Living Inc. generated $3.19B in revenue (+2.2% YoY), -$262.7M in net income, and $16.5M in free cash flow against $5.95B in total assets and $4.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BKD trading relative to its 50-day, 200-day, and 52-week technical levels?

BKD last traded at $10.44 (+0.48% on volume of 5,472,430 shares), positioning the stock -5.09% below its 50-day simple moving average ($11.00) and -21.56% below its 200-day simple moving average ($13.31). Across its 52-week range of $8.02 to $17.09, BKD sits at the 26.7% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±6.7% ($9.74 to $11.14).

Direct Sub-Reports: BKD RQD Cockpit BKD 12M Forecast BKD Earnings & Move BKD Dividends & DRIP BKD Insiders & 13F BKD Whale Options BKD Profit Sankey BKD News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

BKD β€” Brookdale Senior Living Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Brookdale Senior Living Inc. (BKD) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $10.44 (+0.48% 1D, market capitalization $2.48B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 0.3%, gross margin of 26.2%, operating margin of 0.4%, and free cash flow yield of 0.67%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Brookdale Senior Living Inc. (BKD) is a NYSE-listed issuer in the Health Care sector, operating within the Hospital/Nursing Management industry (per the company profile).

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Brookdale Senior Living Inc. (BKD) reported $3.19B in annual revenue (up from $3.13B in FY2024, +2.2% YoY) and -$262.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.02B revenue, -$189.0M net income) through FY2025, BKD scaled operating cash flow to $218.0M and free cash flow to $16.5M, backed by $5.95B in total assets against $4.22B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.67% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $8.02 – $17.09 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 34.6x EV/EBITDA against 0.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” The Butterfly Supply-Chain Graph records no upstream or downstream links, no sector correlations, and no proprietary signals for BKD.

  • Key Question #1: Can BKD sustain or expand its 0.4% operating margin and 0.3% ROIC against Hospital/Nursing Management peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.19B and free cash flow of $16.5M, how will capital allocation balance growth reinvestment against $4.22B in total debt?
  • Key Question #3: How sensitive is BKD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BKD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Brookdale Senior Living Inc. (BKD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BKD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BKD Bull vs. Bear Conversation Board β€” What's Your Call at $10.44?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BKD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BKD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $12.26 (+18.0%)
πŸ“Œ Pinned Debate

Recent headlines point to stronger occupancy results that could support a margin and cash-flow recovery from the current near-zero ROIC

Here is why I am bullish on BKD here at $10.39: Recent headlines point to stronger occupancy results that could support a margin and cash-flow recovery from the current near-zero ROIC.. Compare BKD's 0.4% operating margin and 0.3% ROIC against the rest of Hospital/Nursing Management. As long as cash conversion holds up, dips toward $9.87 are getting bought.

CapAlloc_Nerd πŸ‚ BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Hospital/Nursing Management. If gross margin (26.2%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $8.00 (-23.0%)
Spot @ $10.39

Negative net income in every reported period, an Altman Z of 0.2, and a 34.6 EV/EBITDA leave little margin for error if the recovery st

Careful chasing BKD at $10.39. Negative net income in every reported period, an Altman Z of 0.2, and a 34.6 EV/EBITDA leave little margin for error if the recovery stalls.. Gross margin is 26.2%, but operating margin is 0.4%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.00 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%